ChromaDex - Stock Price History | CDXC

Historical daily share price chart and data for ChromaDex since 2021 adjusted for splits. The latest closing stock price for ChromaDex as of October 26, 2021 is 6.20.
  • The all-time high ChromaDex stock closing price was 18.74 on February 25, 2021.
  • The ChromaDex 52-week high stock price is 23.66, which is 281.6% above the current share price.
  • The ChromaDex 52-week low stock price is 4.36, which is 29.7% below the current share price.
  • The average ChromaDex stock price for the last 52 weeks is 7.56.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
ChromaDex Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 4.5092 4.3000 5.5600 2.5400 4.8000 11.37%
2019 3.9247 3.4100 4.8300 2.8300 4.3100 25.66%
2018 4.1923 6.3500 6.4600 2.8000 3.4300 -41.67%
2017 3.7686 3.4500 6.9600 2.2600 5.8800 77.64%
2016 3.6186 4.4800 5.7600 2.3100 3.3100 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.423B $0.059B
ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, `green`, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86